Moreover, we found that BDNF expression was strongly correlated with CCR2, CXCR2, and CXCR4, and the inhibitors of these chemokine receptors were already evaluated in many preclinical studies and clinical trials for PAAD [37–39]. This evidence concerns the gene CXCR2 and pancreatic adenocarcinoma.